



## Twist Bioscience Launches Express Genes Rapid Gene Synthesis Service

November 14, 2023

Clonally perfect genes shipped in as few as five business days

Launch of 'fast genes' enabled by state-of-the-art Wilsonville manufacturing facility

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 14, 2023-- [Twist Bioscience Corporation](#) (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of [Twist Express Genes](#), a new leading gene synthesis service with an order to shipping turnaround time of five to seven business days.<sup>1</sup>

"Twist Express Genes is our first new offering enabled by the increased capacity and streamlined processes in our Wilsonville facility. We are now able to deliver the same NGS-verified clonally perfect genes that our customers have come to expect from Twist in about half the time, at an unprecedented scale. We offer the rapid turnaround that our customers need in multiple formats and at the same speed for one or thousands of genes. With this new offering, we will focus initially on our current customers who we know are making some of their own genes," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "We look forward to enabling the 'Maker's Market' to continue to push the boundaries of what's possible, working to uncover new therapeutic modalities for devastating diseases, ushering in sustainable applications for enzyme engineering and chemical development, and much more. They clone their own genes because otherwise they would have to delay their research while waiting for genes they ordered, and now they won't have to make that compromise."

Twist leverages its ability to miniaturize the chemical reaction to creating DNA using its silicon-based DNA synthesis platform along with expertise, software, honed processes and the expanded layout of its Wilsonville facility to deliver clonal genes and gene fragments at scale and with rapid turnaround times. Twist will utilize dynamic pricing for Express Genes, charging a premium price for speed, which will be determined by market demand and manufacturing capacity. Customers will be able to place orders for Express Genes through Twist's ecommerce platform.

"We surveyed several hundred gene users and found that in addition to those who make their own genes entirely, a large portion of respondents both purchase DNA from a supplier and in parallel make their own," said Anne St Louis, Director at Percepta Associates Inc.<sup>2</sup> "These data suggest that there is a market to capture from researchers in industry and academia who currently use vendors for only part of their total gene production."

"As a gene therapy startup developing programmable RNA medicines, we routinely generate diverse and customized DNA sequences to advance our technologies and enable application to multiple disease targets. Being able to order sequence-verified large synthetic gene constructs in just one week expands what we can screen and allows faster iterations of the design-build-test cycle," said Susan Byrne, Senior Principal Scientist, Shape Therapeutics.

### Twist Express Genes

[Twist Express Genes](#) are 0.3 to 5.0kb in length. Due to scale enabled by Twist's platform, orders of any size both small and large can be filled, and as with standard speed Twist Clonal Genes, Twist Express Genes are NGS sequence-verified as one hundred percent accurate. Twist Express Genes can be cloned into catalog vectors or custom vectors so that customers can move right to experimentation. They can also be shipped in customers' preferred delivery formats, including tube and plate.

### Current turnaround times for some Twist Bioscience products:

- Express Genes: order to shipping starting at 5 business days
- Standard speed Clonal Genes: starting at 10 business days
- Gene Fragments: starting at 2 business days with an error rate of 1:7,500<sup>3</sup>
- Oligo Pools up to 300nt: starting at 3 business days with an error rate of 1:3,000<sup>4</sup>

Twist quantified the minimal carbon footprint of manufacturing a single gene in its 2023 ESG report. View the report here: <https://www.twistbioscience.com/company/esg?tab=environmental>

<sup>1</sup>Express Genes ship in 5-7 business days. This time will vary based on complexity and length of the sequence. Orders placed outside of the US may incur additional delivery turnaround time.

<sup>2</sup>Research funded by Twist Bioscience

<sup>3</sup>Error rate from <https://www.twistbioscience.com/products/genes?tab=fragment>

<sup>4</sup>Error rate from <https://www.twistbioscience.com/products/oligopools?tab=oligo-pools>

### About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic

DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on [Twitter](#) | [Facebook](#) | [LinkedIn](#) | [YouTube](#)

### **Twist Bioscience Legal Notice Regarding Forward-Looking Statements**

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including statements regarding the turnaround time of the Twist Express Gene product, and Twist’s ability to service researchers currently making their own genes, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to achieve the expected benefits of Twist Bioscience’s workforce reduction and reduced investments in DNA data storage; the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of significant customers; the ability of Twist Bioscience to successfully integrate acquired companies and to achieve expected benefits from acquisitions; supply chain and other disruptions caused by the COVID-19 pandemic or otherwise; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2023 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20231114228857/en/): <https://www.businesswire.com/news/home/20231114228857/en/>

#### **For Investors:**

Angela Bitting  
SVP, Corporate Affairs  
925-202-6211  
[abitting@twistbioscience.com](mailto:abitting@twistbioscience.com)

#### **For Media:**

Amanda Houlihan  
Communications Generalist  
774-265-5334  
[ahoulihan@twistbioscience.com](mailto:ahoulihan@twistbioscience.com)

Source: Twist Bioscience Corporation